

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 November 2003 (13.11.2003)

PCT

(10) International Publication Number
WO 03/093233 A1

(51) International Patent Classification⁷: **C07D 207/34**

(21) International Application Number: PCT/EP03/04313

(22) International Filing Date: 25 April 2003 (25.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
MI2002A000907 29 April 2002 (29.04.2002) IT

(71) Applicant (for all designated States except US): **CHEMI S.P.A.** [IT/IT]; Via dei Laboratori, 54, I-20092 Cinisello Balsamo (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TURCHETTA, Stefano** [IT/IT]; Piazza Vinci, 13, I-00133 Roma (IT).

MASSARDO, Pietro [IT/IT]; Via O. Beccari, 24, I-00154 Roma (IT). **TUOZZI, Angela** [IT/IT]; Via D. Modugno, 8, I-00125 Roma (IT).


(74) Agent: **GERVASI, Gemma**; Notarbartolo & Gervasi S.p.A., Corso di Porta Vittoria, 9, I-20122 Milan (IT).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

[Continued on next page]

(54) Title: PROCESS FOR THE PREPARATION OF THE AMORPHOUS FORM OF ATORVASTATIN CALCIUM SALT



(57) Abstract: Process for preparing atorvastatin calcium salt in amorphous form comprising: a) dissolving the atorvastatin calcium salt in an organic solvent miscible with water, b) gradually adding said solution to water while stirring, c) filtering and vacuum drying the solid obtained. Formula.





SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PROCESS FOR THE PREPARATION OF THE AMORPHOUS FORM OF ATORVASTATIN CALCIUM SALT.

FIELD OF THE INVENTION

The present invention relates to a reproducible method for preparing the
5 amorphous form of atorvastatin calcium salt, in such a way as to be easily filtered,
and with a purity superior to the initial crystalline form.

STATE OF THE ART

Atorvastatin is a well known active pharmaceutical principle widely used for the
treatment of diseases caused by hypercholesterolaemia. US4681893,
10 US5273995, US6121461, US5969156 refer to the preparation of the product both
in amorphous and crystalline form. While the production of a composition with a
well defined crystalline form can in many cases be advantageous from the point of
view of stability and from the point of view of the dosage of the active principle in
the pharmaceutical formulation, in some cases this can give rise to water solubility
15 and bioavailability differences. This is the case with atorvastatin where the
corresponding amorphous form demonstrates superior characteristics of water
solubility and bioavailability than the corresponding crystalline form. On the other
hand the known processes for producing atorvastatin in amorphous form present
problems due to the poor reproducibility and/or poor workability of the product or
20 are not suitable for scale up to industrial production.

For example in US6087511 and US6274740 are described the preparation of the
amorphous form of atorvastatin calcium salt starting from the crystalline form (I) by
evaporating the solution of the product in organic solvents such as tetrahydrofuran
or tetrahydrofuran-toluene, until a foamy solid residue is obtained. This method
25 presents considerable drawbacks from the point of view of industrial application.
In regard to the workability of the product, at the end of the preparation a fragile
foam is obtained which must be broken up in the reactor and must be discharged
from the reactor as a solid.

WO007116 reports the production of atorvastatin in amorphous form from a
30 solution of the product in a non-hydroxylic solvent. In this case high levels of
hydrocarbon are necessary to obtain the desired product.

WO0128999 describes the preparation of amorphous atorvastatin by precipitating

the product from solutions of atorvastatin calcium salt in lower alkanols. In this case enormous quantities of alcohols are necessary to obtain the desired product.

TECHNICAL PROBLEM

It was therefore considered necessary to provide a method for producing atorvastatin in amorphous form that was economically advantageous and at the same time industrially scalable.

SUMMARY OF THE INVENTION

The applicant has unexpectedly found that atorvastatin calcium salt can be produced in amorphous form, by a method that does not present the inconveniences of the state of the art.

In particular the process of the present invention comprises:

- a) dissolving the atorvastatin calcium salt in an organic solvent miscible with water,
- b) gradually adding said solution to water while stirring,
- c) filtering and vacuum drying the solid obtained.

DESCRIPTION OF THE FIGURE

Figure 1 shows the x-ray diffraction spectrum of the amorphous atorvastatin prepared as described in example 1.

The measurements were made at the wavelengths $K\alpha_1$ and $K\alpha_2$ using 5.000° for angle 2θ and 35.000° for the final angle. In this figure, in ordinates the number of

counts per second is reported, and in abscissae the values of the angle 2θ .

DETAILED DESCRIPTION OF THE INVENTION

The atorvastatin used as starting material can be either crystalline or amorphous.

Consequently the atorvastatin used in stage (a) of the process of the present invention can therefore be crystalline atorvastatin of form (I), (II) and (IV) as described in US5969156 form (III) as described in US6121461 or the amorphous form derived from the reaction described in US5273995.

Preferably this latter type of atorvastatin is used.

The water miscible solvent is preferably chosen from: tetrahydrofuran, dimethylsulphoxide, dimethylacetamide, dimethylformamide, N-methylpyrrolidone, sulfolane. The additional advantage of this method is that the product obtained, whose amorphous nature is confirmed by the relative x-ray diffraction spectrum, has a higher purity than the starting product.

Preferably the atorvastatin calcium salt is dissolved in a quantity of organic solvent between 0.5 and 20, more preferably between 1 and 10 and even more preferably between 1 and 5 ml/gram of the atorvastatin calcium salt in crystalline form. The amount of water, to which the atorvastatin in organic solvent is slowly added, is preferably between 5 and 100, more preferably between 10 and 50, and even more preferably between 10 and 30 ml/gram of atorvastatin calcium salt in crystalline form. The temperature of the constantly stirred water is between 5 and 40°C, preferably between 10 and 30°C. Preferably the water soluble organic solvent is tetrahydrofuran. As the solution of atorvastatin calcium salt in the organic solvent is dripped onto the stirred water, the formation of a solid is observed which becomes more consistent as the addition proceeds. At the end of the addition the mixture is stirred for a period of time between 0.5 and 5 hours, preferably between 1 and 3 hours and even more preferably between 2 and 3 hours at a temperature of between 5 and 40°C and preferably between 10 and 30°C, after which the suspension is filtered and the solid washed with water.

A further advantage of this method lies in the good filterability of the solid obtained due to the addition of the organic solution to the water. Indeed the addition of water to the organic solution results in the formation of gummy masses which cannot be filtered or stirred.

Some illustrative but non-limitative examples are given hereinafter of the preparation process according to the present invention.

EXAMPLE 1

5 g of crude amorphous atorvastatin calcium salt derived from the reaction mixture of the process described in US5273995 are dissolved in 15 ml of THF and loaded into a dropping funnel. The funnel is placed above a 250 ml reaction flask equipped with mechanical stirrer. 100 ml of deionized water are loaded into the reactor and maintained at 22-25°C and from the dropping funnel the THF solution is added to the water, resulting in the formation of a white solid. When the addition is complete the suspension is cooled to 10°C while stirring and maintained at that temperature for 1 hour. The precipitate is then filtered off under reduced pressure and washed with 20 ml of deionized water. 13.4 g of a wet product is obtained which, after drying for 12 hours at 40°C under reduced pressure (50mm Hg) gives

rise to 4.8 g of atorvastatin calcium salt in amorphous form (yield 95%), of a purity superior to that of the initial crude atorvastatin evaluated by means of TLC as comparison.

Figure 1 shows the x-ray diffraction spectrum of the atorvastatin calcium salt in amorphous form thus obtained, a spectrum which is entirely in accordance with those already reported in the literature for such a product.

EXAMPLE 2

A 500 ml reactor equipped with mechanical stirrer and dropping funnel is filled with 200 ml of deionized water, maintained at 22-25°C. 20g of crude amorphous atorvastatin calcium salt derived from the reaction mixture of the process described in US5273995 are dissolved in 30 ml of N,N-dimethylacetamide and loaded into the dropping funnel. The organic solution is then slowly dripped onto the water and a white solid is formed. At the end of the addition the mixture is stirred for about 1 hour at 22-25°C and is then cooled to 10°C and maintained at that temperature for 1 hour. The solid is filtered off, washed with 50 ml of cold deionized water and dried under vacuum at 40°C for 12 hours to give 18.2g of atorvastatin calcium salt in amorphous form (yield 91%) of a purity superior to the initial crude atorvastatin evaluated by means of TLC as comparison.

EXAMPLE 3

The reaction is conducted starting from 20 g of atorvastatin calcium salt using the same conditions as in example 2, with the only difference that dimethylsulphoxide is used as the organic solvent miscible in water. After drying, 17.5 g of atorvastatin calcium salt in amorphous form are obtained (yield 87.5%) of a purity superior to the initial crude atorvastatin evaluated by means of TLC as comparison.

CLAIMS

1. Process for preparing atorvastatin calcium salt in amorphous form comprising
 - a) dissolving the atorvastatin calcium salt in an organic solvent miscible with water,
 - b) gradually adding said solution to water while stirring,
 - 5 c) filtering and vacuum drying the solid obtained.
2. Process as claimed in claim 1, characterised in that atorvastatin used in stage (a) is amorphous atorvastatin.
3. Process as claimed in claim 1 or 2, characterised in that the water miscible solvent is preferably chosen from the class consisting of tetrahydrofuran,
10 dimethylsulphoxide, dimethylacetamide, dimethylformamide, N-methylpyrrolidone, sulfolane.
4. Process as claimed in claim 3 wherein said water miscible organic solvent is tetrahydrofuran.
5. Process as claimed in any one of claims 1-4, characterised in that in stage (a)
15 atorvastatin calcium salt is dissolved in a quantity of water miscible organic solvent of between 0.5 and 20 ml/gram of atorvastatin calcium salt in crystalline form.
6. Process as claimed in claim 5, characterised in that said quantity of organic solvent is between 1 and 10 ml/gram of atorvastatin calcium salt in crystalline form.
- 20 7. Process as claimed in claim 6, characterised in that said quantity of organic solvent is between 1 and 5 ml/gram of atorvastatin calcium salt in crystalline form.
8. Process as claimed in any one of claims 1-7 characterised in that in stage (a) the quantity of water, to which the solution of atorvastatin in organic solvent is slowly added, is between 5 and 100 ml/gram of atorvastatin calcium salt in
25 crystalline form.
9. Process as claimed in claim 8, characterised in that said quantity of water is between 10 and 50 ml/gram of atorvastatin calcium salt in crystalline form.
10. Process as claimed in claim 9, characterised in that said quantity of water is between 10 and 30 ml/gram of atorvastatin calcium salt in crystalline form
- 30 11. Process as claimed in any one of claims 1-10, characterised in that the water temperature in stage (a) is between 5 and 40°C.
12. Process as claimed in claim 11, characterised in that the said temperature is

between 10 and 30°C.

13. Process as claimed in any one of claims 1-10 characterised in that when stage (a) has terminated, the mixture obtained is left under stirring at a temperature between 5 and 40°C for a period of time between 0.5 and 5 hours.

- 5 14. Process as claimed in claim 13, characterised in that when stage (a) has terminated, the mixture obtained is left under stirring at a temperature between 10 and 30°C for a time period between 1 and 3 hours.




FIG 1

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D207/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01 042209 A (LEK PHARMACEUTICAL AND CHEMICAL COMPANY D.D., SLOVENIA) 14 June 2001 (2001-06-14) page 3, line 5 - line 16 page 7, line 3 - line 33; claims 1,7,16 ---	1-14
A	WO 01 028999 A (EGIS GYOGYSZERGYAR RT., HUNG.;ET AL.) 26 April 2001 (2001-04-26) cited in the application page 5, line 3 - line 8; claim 1 ---	1-14
Y	WO 00 71116 A (THAPER RAJESH KUMAR ;KUMAR YATENDRA (IN); RANBAXY LAB LTD (IN); KU) 30 November 2000 (2000-11-30) cited in the application claims 1-6 --- -/--	1-14

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

13 August 2003

Date of mailing of the international search report

27/08/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Schuemacher, A

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6 274 740 B1 (LIN MIN ET AL) 14 August 2001 (2001-08-14) cited in the application claim 1; example 2 ----	1-14
P,Y	WO 03 018547 A (MOREPEN LABORATORIES LTD., INDIA) 6 March 2003 (2003-03-06) see process 2, p.4. claim 2; examples I,II ----	1-14
P,A	WO 02 059087 A (LEK PHARMACEUTICAL AND CHEMICAL COMPANY D.D., SLOVENIA) 1 August 2002 (2002-08-01) page 3, line 24 -page 4, line 15; claims 1,7-9,15; examples 1,2 -----	1-14

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 01042209	A	14-06-2001	SI 20425 A	30-06-2001
			AU 1543801 A	18-06-2001
			BG 106786 A	30-05-2003
			CA 2392025 A1	14-06-2001
			EE 200200293 A	16-06-2003
			EP 1237864 A1	11-09-2002
			WO 0142209 A1	14-06-2001
			JP 2003516388 T	13-05-2003
			SK 7832002 A3	06-11-2002
			US 2002183527 A1	05-12-2002
WO 01028999	A	26-04-2001	HU 9903634 A2	28-12-2001
			AU 1166301 A	30-04-2001
			CA 2388018 A1	26-04-2001
			CN 1379760 T	13-11-2002
			CZ 20021256 A3	14-08-2002
			EP 1235800 A1	04-09-2002
			WO 0128999 A1	26-04-2001
			JP 2003512354 T	02-04-2003
			SK 5192002 A3	06-11-2002
WO 0071116	A	30-11-2000	AU 1996700 A	12-12-2000
			BR 0010923 A	16-07-2002
			CN 1351493 T	29-05-2002
			EP 1185264 A1	13-03-2002
			WO 0071116 A1	30-11-2000
			US 6528660 B1	04-03-2003
US 6274740	B1	14-08-2001	AT 199542 T	15-03-2001
			AU 700794 B2	14-01-1999
			AU 6497896 A	18-02-1997
			BG 63631 B1	31-07-2002
			BG 102188 A	31-08-1998
			BR 9609714 A	23-02-1999
			CA 2220455 A1	06-02-1997
			CN 1190956 A ,B	19-08-1998
			CZ 9800122 A3	16-12-1998
			DE 69611999 D1	12-04-2001
			DE 69611999 T2	26-07-2001
			DK 839132 T3	09-04-2001
			EA 625 B1	29-12-1999
			EE 9700369 A	15-06-1998
			EP 0839132 A1	06-05-1998
			ES 2156997 T3	01-08-2001
			GR 3035859 T3	31-08-2001
			HR 960312 A1	28-02-1998
			HU 220343 B	28-12-2001
			IL 122161 A	14-07-1999
			JP 11510486 T	14-09-1999
			NO 980209 A	16-01-1998
			NZ 313008 A	28-01-2000
			PL 324463 A1	25-05-1998
			PT 839132 T	29-06-2001
			SI 839132 T1	30-06-2001
			SK 5898 A3	05-08-1998
			WO 9703960 A1	06-02-1997
WO 03018547	A	06-03-2003	WO 03018547 A2	06-03-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
W0 02059087	A	01-08-2002	SI 20814 A	31-08-2002
			W0 02059087 A1	01-08-2002
			US 2003109569 A1	12-06-2003
<hr/>				